A phase I clinical study to evaluate the tolerability, safety and preliminary efficacy of multiple local administrations of CG0070 injection in patients with BCG-unresponsive non-muscle invasive bladder cancer
Latest Information Update: 17 Feb 2025
Price :
$35 *
At a glance
- Drugs Cretostimogene grenadenorepvec (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
- 17 Feb 2025 New trial record